國立高雄大學圖資館 |

登入

回首頁

Sustainable global health systems and pharmaceutical development

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Sustainable global health systems and pharmaceutical developmentby Bhavishya Mittal.
作者:	Mittal, Bhavishya.
出版者:	Cham :Springer International Publishing :2024.
面頁冊數:	xxix, 247 p. :ill. (chiefly col.), digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Drug developmentEconomic aspects.
電子資源:	https://doi.org/10.1007/978-3-031-50415-0
ISBN:	9783031504150$q(electronic bk.)

Sustainable global health systems and pharmaceutical development
Mittal, Bhavishya.

Sustainable global health systems and pharmaceutical development[electronic resource] /by Bhavishya Mittal. - Cham :Springer International Publishing :2024. - xxix, 247 p. :ill. (chiefly col.), digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v. 602210-738X ;. - AAPS advances in the pharmaceutical sciences series ;3..

Health Care Industry -- Reimbursement and Pricing -- Current Stage of Pharmaceutical Development -- Desired Future State of Pharmaceutical Development -- Case Studies I -- Case Studies II -- Case Studies III.

Despite being an economically intense activity, the current state of drug product development makes a limited effort to integrate economics into product design and development. For example, pharmaceutical scientists are excellent at a data-driven decision-making process that requires technical elements and a few strategic elements. However, there is minimal integration of financial valuation elements (commonly employed in other high tech industries such as fine chemicals, automotive, aerospace, etc.) into pharmaceutical drug development. Unfortunately, this hurts the sustainability of the health system of which these products will be a part in the future. A desirable future state is the one that integrates fundamentals of economics in product design and development so that the decision-making is parameterized, the cost of goods could be lowered, wastage can be reduced, patient-centricity is built into the design, and manufacturing/distribution efficiencies can be gained. The financial benefits of such an approach could allow for these savings to be passed on to the stakeholders and improve the value proposition of pharmaceuticals, which is critical to maintaining the innovation potential. This book hopes to introduce the reader to this desired future state of pharmaceutical drug development.

ISBN: 9783031504150$q(electronic bk.)

Standard No.: 10.1007/978-3-031-50415-0doiSubjects--Topical Terms:

785709
Drug development
--Economic aspects.

LC Class. No.: RM301.25

Dewey Class. No.: 338.476151

Sustainable global health systems and pharmaceutical development
LDR:02654nmm a22003495a 4500 001 667524
003 DE-He213
005 20240903130455.0
006 m d
007 cr nn 008maaau
008 250107s2024 sz s 0 eng d
020 $a 9783031504150$q(electronic bk.)
020 $a 9783031504143$q(paper)
024 7 $a 10.1007/978-3-031-50415-0 $2 doi
035 $a 978-3-031-50415-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 338.476151 $2 23
090 $a RM301.25 $b .M685 2024
100 1 $a Mittal, Bhavishya. $3 980431
245 1 0 $a Sustainable global health systems and pharmaceutical development $h [electronic resource] / $c by Bhavishya Mittal.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2024.
300 $a xxix, 247 p. : $b ill. (chiefly col.), digital ; $c 24 cm.
347 $a text file $b PDF $2 rda
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-738X ; $v v. 60
505 0 $a Health Care Industry -- Reimbursement and Pricing -- Current Stage of Pharmaceutical Development -- Desired Future State of Pharmaceutical Development -- Case Studies I -- Case Studies II -- Case Studies III.
520 $a Despite being an economically intense activity, the current state of drug product development makes a limited effort to integrate economics into product design and development. For example, pharmaceutical scientists are excellent at a data-driven decision-making process that requires technical elements and a few strategic elements. However, there is minimal integration of financial valuation elements (commonly employed in other high tech industries such as fine chemicals, automotive, aerospace, etc.) into pharmaceutical drug development. Unfortunately, this hurts the sustainability of the health system of which these products will be a part in the future. A desirable future state is the one that integrates fundamentals of economics in product design and development so that the decision-making is parameterized, the cost of goods could be lowered, wastage can be reduced, patient-centricity is built into the design, and manufacturing/distribution efficiencies can be gained. The financial benefits of such an approach could allow for these savings to be passed on to the stakeholders and improve the value proposition of pharmaceuticals, which is critical to maintaining the innovation potential. This book hopes to introduce the reader to this desired future state of pharmaceutical drug development.
650 0 $a Drug development $x Economic aspects. $3 785709
650 1 4 $a Pharmacology. $3 218135
650 2 4 $a Pharmacy. $3 218145
650 2 4 $a Public Health. $3 320661
650 2 4 $a Pharmaceutics. $3 913065
650 2 4 $a Epidemiology. $3 191577
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v 3. $3 559046
856 4 0 $u https://doi.org/10.1007/978-3-031-50415-0
950 $a Biomedical and Life Sciences (SpringerNature-11642)